Further studies showed that the effect of dasatinib in HCC in vitro and in vivo is limited by the over-activation of FAK pathway and that its anticancer potential can be enhanced in combination with FAK inhibitors (Liu et al., 2018). Here, PTK2 is linked to hepatocellular carcinoma.